In contrast,activating BCR pathway mutations which are common in diffuse large B cell lymphoma(DLBCL) generally does not appear to play a role in CLL patients (Philippen et al.2010), except as a treatmentresistance mechanism in patients receiving BCR-signaling-targeted therapy. This evidence concerns the gene BCR and diffuse large B-cell lymphoma.